About Yatharth Hospital and Trauma Care Services Limited 

Yatharth Hospital and Trauma Care Services Limited is a super speciality hospital network founded on February 28, 2008, with registered office in Jasola, Delhi, and corporate operations in Noida, Uttar Pradesh, operating across Delhi NCR and Madhya Pradesh as of March 31, 2025. Its hospitals are NABH accredited, with Noida Extension additionally JCI accredited, and the network is equipped with advanced technologies such as Da Vinci, Mako and Cuvis robotic surgery platforms, Azurion cath lab, 1.5 Tesla MRI, and 128-slice CT to support comprehensive tertiary care. The company runs seven network hospitals with a total capacity of 2,305 beds, including 640 critical care beds, serving IPD and OPD patients across specialities such as Oncology, Cardiology, Neurosciences, Orthopaedics, Gastroenterology, Nephrology, Urology, and transplant programmes.

The company’s footprint spans Noida (Sector 110), Greater Noida (Omega-1), Noida Extension, Jhansi-Orchha, Faridabad (Sector 88), a new unit in North Delhi (Model Town), and an additional unit in Faridabad (Sector 20B), with the Delhi hospital inaugurated in July 2025 and a Faridabad hospital planned for September 2025. The network leverages NCR’s referral hub dynamics to draw patients from Uttar Pradesh, Delhi, Haryana, Uttarakhand and beyond. The company reports an export contribution of 0.51% of turnover and focuses entirely on hospital healthcare services under NIC 8610.

As on March 31, 2025, the company lists five subsidiaries: AKS Medical Research Centre Pvt. Ltd. (material, 100%), Ramraja Multispeciality Hospital (100%), Pristine Infracon Private Limited (100%), Sanskar Medica India Limited (100%), and MGS Infotech Research Centre Private Limited (60%). The company’s FY 2025 standalone revenue from operations was Rs 45.42 crore (per financial statements unit header in H million; see note below), while consolidated indicators in the MD&A mention revenue Rs 8,805 million alongside EBITDA and PAT trends; the company also completed a Qualified Institutional Placement during FY 2025 to strengthen equity and prepay borrowings. Key milestones include commissioning the Noida (2013), Greater Noida (2010), and Noida Extension (2019) units, expansion to Jhansi-Orchha (2022), and the acquisition/commissioning of Faridabad (2024) with ongoing upgrades for oncology and robotics.

Yatharth Hospital and Trauma Care Services Limited Business Segment

• The company operates a single segment: hospital activity and healthcare services accounting for 100% of turnover, with diagnostics and pharmacy integrated into care pathways as part of hospital operations.

• Geographic split: Exports contributed 0.51% of total turnover; the report does not provide a domestic vs. international revenue amount split in Rs crore terms, hence no percentage allocation is presented.

Yatharth Hospital and Trauma Care Services Limited Key Management

• Dr. Ajay Kumar Tyagi — Chairman and Whole-time Director.

• Dr. Kapil Kumar — Managing Director.

• Yatharth Tyagi — Whole-time Director.

• Amit Kumar Singh — Chief Executive Officer.

• Pankaj Prabhakar — Chief Financial Officer.

• Ritesh Mishra — Company Secretary and Compliance Officer.

Latest Updates on Yatharth Hospital and Trauma Care Services Limited

• Acquired and operationalised a 200-bed Faridabad hospital in May 2024, NABH accredited with 61 ICUs, being developed into a super speciality centre with oncology and robotic surgeries.

• Inaugurated a hospital in North Delhi (Model Town) in July 2025, with another Faridabad unit planned for September 2025, expanding NCR presence.

• Completed a Qualified Institutional Placement in FY 2025, used to prepay borrowings and strengthen the balance sheet, reducing debt-equity to near zero.

• JCI accreditation maintained at Noida Extension; continued NABH accreditations across the network; enhanced robotics and advanced diagnostics capabilities network-wide.

Consolidated operating performance improved with higher ARPOB, strong occupancy despite capacity addition, and increased contribution from high-value specialties like oncology in FY 2025.